Archives of Dermatological Research最新文献

{"title":"Equivalence of measurement properties of the Dermatology Life Quality Index (DLQI) across 13 European countries","authors":"Sam Salek,&nbsp;Jeffrey Johns,&nbsp;Faraz M. Ali,&nbsp;Florence J. Dalgard,&nbsp;Jörg Kupfer,&nbsp;Andrew Y. Finlay","doi":"10.1007/s00403-026-04877-0","DOIUrl":"10.1007/s00403-026-04877-0","url":null,"abstract":"<div><p>The Dermatology Life Quality Index (DLQI) is the most widely used tool to measure burden of skin diseases and assess intervention effectiveness. It is embedded in national guidelines and disease registries in &gt; 45 countries and available in &gt; 138 translations. This study examined psychometric properties of the DLQI across 13 European languages. 3,408 patients had completed the DLQI questionnaire with no missing data. Confirmatory factor analysis (CFA) was performed using datasets of each country and multigroup CFA (MGCFA) across all countries. Known-group analysis was performed of DLQI sum-score against physician-assessed severity by country. All countries’ DLQI data showed essential unidimensionality with good fits to a 1-factor CFA model with CFI, TLI unscaled values all &gt; 0.97 (COSMIN criteria). MGCFA indicated different country translations of the DLQI conceptualize the same construct and showed equality of factor loadings. Although, scalar invariance was not seen, meaning that direct comparison of mean DLQI scores across 12 countries is not supported by the current results, partial scalar invariance was achieved after constraining one threshold for DLQI item 7. Known-group analysis of DLQI versus disease severity was significant for every country (all <i>p</i> &lt; 0.025). Good psychometric properties were present across all 13 languages examined with essential unidimensionality confirmed. The DLQI differentiated between levels of disease severity and EQ-5D-3 L levels across all these languages. This adds further confidence in the appropriateness of using the DLQI with this range of languages.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-026-04877-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety events at a dermatology practice: a retrospective cross-sectional analysis of safety event reporting trends and barriers","authors":"Alyssa M. Iurillo,&nbsp;Samer Wahood,&nbsp;Megan Hoang,&nbsp;Fatima N. Mirza,&nbsp;Megan M. Tran,&nbsp;Lauryn Orsillo,&nbsp;Tatiana Abrantes,&nbsp;Sara Yumeen,&nbsp;Eric Yang,&nbsp;Christopher DiMarco,&nbsp;Nicole L. Grenier,&nbsp;John C. Kawaoka,&nbsp;Su-Jean Seo,&nbsp;Abrar Qureshi,&nbsp;Daniel Labrador,&nbsp;Oliver J. Wisco","doi":"10.1007/s00403-026-04992-y","DOIUrl":"10.1007/s00403-026-04992-y","url":null,"abstract":"<div><p>Adverse event reporting plays a critical role in maintaining patient safety and promoting continuous improvement in healthcare settings. This retrospective cross-sectional quality improvement study analyzed five years of adverse event reports (2017–2022) at an academic dermatology department in Rhode Island. Using department-generated paper-based forms, the study assessed the frequency, type, severity, and origin of safety incidents to identify prevailing trends and opportunities for system refinement. A total of 78 events were reported, with the most common categories being pathology-related errors, needlestick injuries, and non-needlestick injuries. Most events (60.30%) were categorized as ‘no harm’ with no severe harm or deaths reported. The prevalence of low and moderate harm events—including specimen mislabeling and the need for repeat biopsies—underscores ongoing safety vulnerabilities. Notably, pathology-related issues such as lost or mislabeled specimens comprised a significant portion of reports, echoing broader concerns about sample handling and labeling errors. Reporting patterns revealed disparities among staff roles: attendings and medical assistants submitted the majority of reports, while residents contributed fewer, possibly due to educational or logistical barriers. The number of events peaked in 2019 and declined during the COVID-19 pandemic, reflecting broader disruptions in healthcare delivery. Underreporting remains a key concern, with systemic limitations such as difficulty accessing paper forms, lack of structured feedback, and fear of repercussions as likely contributing factors. To address these limitations, the department transitioned to an electronic adverse event reporting system in 2023, integrating structured dropdown categories and automated data capture. This digital system was modeled in part on safety protocols used in aviation, prioritizing accessibility, standardization, and a non-punitive environment. The new system facilitates more efficient tracking, analysis, and follow-up of safety events and may serve as a template for other outpatient specialty clinics. This study highlights the critical need to improve dermatology-specific safety reporting systems and calls for broader efforts to encourage reporting across all roles. The insights gathered lay the groundwork for more robust quality improvement initiatives, both locally and across institutional networks.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperpigmentation is associated with increased risk of mood disorders: results from a national cohort study utilizing the TriNetX database","authors":"Debby Cheng,&nbsp;Christopher J. Thang,&nbsp;Helen Ji,&nbsp;David A. Hirsh,&nbsp;Yevgeniy R. Semenov,&nbsp;Arash Mostaghimi,&nbsp;Nicholas Theodosakis","doi":"10.1007/s00403-026-04982-0","DOIUrl":"10.1007/s00403-026-04982-0","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beremagene geperpavec (B-VEC): the first topical gene therapy for dystrophic epidermolysis bullosa","authors":"Emily Wang,&nbsp;Jimmy Dhillon,&nbsp;Bianca Sanabria,&nbsp;Gaurav N. Pathak,&nbsp;Babar Rao,&nbsp;Dedee F. Murrell","doi":"10.1007/s00403-026-04864-5","DOIUrl":"10.1007/s00403-026-04864-5","url":null,"abstract":"<div><p>This study aims to provide an overview of the pharmacodynamic and pharmacokinetic properties, clinical efficacy, and safety of beremagene geperpavec-svdt (B-VEC), a topical gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB). A literature review was conducted in ClinicalTrials.gov and PubMed using the search term “Beremagene geperpavec AND dystrophic epidermolysis bullosa” over the period from January 1st, 2000, to July 11th, 2026. Full-text English articles related to the safety and efficacy of B-VEC were included, resulting in the identification of nineteen studies, four of which met the inclusion criteria as unique clinical trials. In a phase I/II trial, B-VEC showed a statistically significant difference in wound response based on responder analysis (<i>P</i> = 0.0026), with a median of 13.5 days to wound closure (95% CI: 8–21) compared to 22.5 days for placebo (95% CI: 8–64). A phase III trial demonstrated a 46% (95% CI: 24–68, <i>P</i> = 0.002) and 51% (95% CI: 29–73, <i>P</i> &lt; 0.001) improvement in complete wound closure with B-VEC at 6 and 3 months, respectively. A subsequent open-label extension study demonstrated that wound-closure was not always permanent, with durability dependent on continued weekly dosing over 112 weeks, though no new safety concerns emerged with extended administration. An independent open-label trial in Japanese patients reported comparable efficacy and safety, supporting generalizability beyond the US population. As the first FDA-approved topical gene therapy for DEB treatment, B-VEC appears to be a well-tolerated and effective treatment option based on available trial data, though these trials have involved small sample sizes, and comparator trials with other therapies are lacking. Overall, B-VEC is a promising but still evolving treatment option for DEB in patients aged 6 months and older, with longer-term, larger-scale, and comparative studies needed to fully define its role.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hearing impairment in individuals with Port-wine stains and Sturge-Weber syndrome","authors":"Ashley N. Houff,&nbsp;Daniela E. Velez,&nbsp;Paxton Guerin,&nbsp;Sameer Gupta,&nbsp;Ian Gupta,&nbsp;Monique Kumar","doi":"10.1007/s00403-026-04914-y","DOIUrl":"10.1007/s00403-026-04914-y","url":null,"abstract":"&lt;div&gt;&lt;p&gt;Port wine stains (PWS) are congenital vascular malformations. Rarely, PWS can occur as part of the neurocutaneous syndrome, Sturge-Weber syndrome (SWS). Most cases of PWS and SWS are driven by mutations in guanine nucleotide-binding protein alpha subunit q (GNAQ). In addition to vascular malformations, there may be other unknown phenotypes associated with GNAQ mutations. The objective of this study is to explore whether there are individuals with PWS or SWS who experience hearing loss or impairment through a review of the literature and a screening survey study. The literature review was conducted using PubMed, and an electronic survey was administered in PWS and SWS support groups on Facebook. The survey explored support group member self-perceived symptoms, asking about PWS or SWS diagnosis, presence of hearing impairment or loss, and hearing loss characteristics (severity, duration, and treatments). Hearing loss characteristic percentages were calculated with a denominator of the total number of respondents with hearing loss (&lt;i&gt;n&lt;/i&gt; = 53). The literature review phase of the study identified reports of hearing loss in 3 individuals with PWS alone and 77 with SWS. The survey had 84 responses included, of which 50 (59.5%) had PWS alone, 31 (36.9%) had PWS and SWS, and 3 (3.6%) had SWS alone. In this self-selected support group sample, 53 respondents reported hearing loss for a sample proportion of 63.1% [95% confidence interval 52.4% − 72.6%]. Due to the non-representative nature of the sample, this interval represents precision of our sample estimate rather than population prevalence. Among the 53 with hearing loss, 36 (67.9%) did not know their hearing loss type. The remainder self-reported sensorineural (&lt;i&gt;n&lt;/i&gt; = 7, 13.2%), mixed (&lt;i&gt;n&lt;/i&gt; = 6, 11.3%), and conductive (&lt;i&gt;n&lt;/i&gt; = 4, 7.5%). Self-perceived hearing loss severity ranged across mild (&lt;i&gt;n&lt;/i&gt; = 21, 39.6%), moderate (&lt;i&gt;n&lt;/i&gt; = 18, 34.0%), severe (&lt;i&gt;n&lt;/i&gt; = 13, 24.5%), and unknown (&lt;i&gt;n&lt;/i&gt; = 1, 1.9%). Most respondents with hearing loss (&lt;i&gt;n&lt;/i&gt; = 21, 39.6%), reported symptom duration of more than 10 years. Most with hearing loss (&lt;i&gt;n&lt;/i&gt; = 34, 64.2%) reported receiving one or more treatments, including hearing aids (&lt;i&gt;n&lt;/i&gt; = 23, 43.4%), medication (&lt;i&gt;n&lt;/i&gt; = 2, 3.8%), cochlear implants (&lt;i&gt;n&lt;/i&gt; = 1, 1.9%), other surgery (&lt;i&gt;n&lt;/i&gt; = 10, 18.9%), and other (&lt;i&gt;n&lt;/i&gt; = 5, 9.4%). The sum adds to more than the percentage with treatment (64.2%) because there were 7 (13.2%) extra responses from selection of multiple treatment types. These data represent self-perceived symptom profiles of support group members and are not confirmed with audiometry or representative of the general population. This study is exploratory and cannot establish prevalence or association. However, this study adds to the limited number of prior reports of hearing loss in individuals with PWS and SWS. Future studies with objective assessments are needed to determine whether hearing loss is associate","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis","authors":"Henry Omar Herrera,&nbsp;Bryan Nolasco,&nbsp;Abizairie Sánchez-Feliciano,&nbsp;Jeremy Bordeaux","doi":"10.1007/s00403-026-04971-3","DOIUrl":"10.1007/s00403-026-04971-3","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of skin microbial shifts in the pathogenesis of atopic dermatitis: a systematic review and meta-analysis","authors":"Nurul Ain Mohd Noor,&nbsp;Nur Najibah Yusra Sulaiman,&nbsp;Siong Meng Lim,&nbsp;Kalavathy Ramasamy,&nbsp;Muhamad Fareez Ismail","doi":"10.1007/s00403-026-04990-0","DOIUrl":"10.1007/s00403-026-04990-0","url":null,"abstract":"<div><p>Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by a disrupted skin barrier, immune dysregulation, and significant microbial dysbiosis. Increasing evidence suggests that shifts in the skin microbiome, notably involving key species such as <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>, play a pivotal role in AD pathogenesis. However, the extent and clinical implications of these microbial shifts remain unclear, necessitating a comprehensive synthesis of current evidence. This systematic review and meta-analysis aimed to synthesize current evidence on the shifts in skin microbiota associated with AD. Four databases, namely PubMed, Cochrane, Disbiome and Scopus were systematically searched from inception to May 2024, restricted to English-language publications. Randomized controlled trials, case-control, and cohort studies investigating microbial diversity and abundance in AD patients compared to healthy controls were included. Study quality was rigorously assessed using validated tools. Meta-analyses were conducted to quantify differences in microbial alpha diversity and <i>S. aureus</i> and <i>S. epidermidis</i> prevalence. From 608 initial records, 23 studies met the inclusion criteria, including 8 randomized controlled trials, 10 case-control studies, and 5 cohort studies. The meta-analysis demonstrated reduced alpha diversity in AD skin (SMD: -1.36, <i>p</i> &lt; 0.00001) and increased <i>S. aureus</i> colonization (SMD: 3.49, <i>p</i> &lt; 0.00001), particularly in lesional skin. <i>S. epidermidis</i> abundance was elevated overall, but it exhibited strain-dependent variability, with some strains exacerbating inflammation. Findings suggest microbial dysbiosis contributes to disease progression, supporting its relevance for clinical interventions. Microbiome-targeted therapies hold promise for integrated AD management, particularly by restoring microbial balance and strengthening the skin barrier.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IFIT1 promotes SLE disease progression by upregulating PBMC apoptosis and inflammatory factor levels","authors":"Ge-Ge Jiang,&nbsp;Zheng Cai,&nbsp;Xiang-wen Meng,&nbsp;Xiao-Yi Jia,&nbsp;Min Zhang","doi":"10.1007/s00403-026-04950-8","DOIUrl":"10.1007/s00403-026-04950-8","url":null,"abstract":"<div><p>This study aims to investigate the expression and mechanisms of Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) in peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE). The expression level of IFIT1 in SLE was analyzed using the GSE121239 dataset. Peripheral blood samples were collected from SLE patients and healthy controls, and IFIT1 expression levels in PBMCs were detected. Clinical indicators were collected for correlation analysis. PBMCs were stimulated with interferon to evaluate the regulation of IFIT1 expression. Flow cytometry was performed to assess apoptosis levels in PBMCs from SLE patients and controls, as well as the effect of IFIT1 knockdown on PBMC apoptosis. ELISA was used to detect the levels of inflammatory cytokines. IFIT1 expression is elevated in PBMCs from SLE patients, Its expression correlates with clinical indicators. IFN-α2b stimulates a gradient upregulation of IFIT1. PBMCs apoptosis level and expression level of inflammatory factors were significantly elevated in SLE patients, and knockdown of IFIT1 lowers them. IFIT1 was highly expressed in PBMCs from SLE patients, and IFIT1 can be upregulated by IFN-α2b stimulation. IFIT1 can elevate the apoptosis level of PBMCs and the expression level of related inflammatory factors in SLE patients, suggesting that IFIT1 may contributes to the disease progression of SLE.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between prurigo nodularis and skin cancer: a propensity score–matched cohort study using the all of us research program","authors":"Mackenzie K Joe,&nbsp;Malak Husseinali,&nbsp;Carina A Wasko","doi":"10.1007/s00403-026-04989-7","DOIUrl":"10.1007/s00403-026-04989-7","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could the use of melatonin be a promising complementary strategy in the prevention of skin cancer?","authors":"Luiza A. Altenfelder,&nbsp;Ellen M. S. Xerfan,&nbsp;Sergio Tufik,&nbsp;Monica L. Andersen","doi":"10.1007/s00403-026-04933-9","DOIUrl":"10.1007/s00403-026-04933-9","url":null,"abstract":"<div><p>Skin cancer, including both non-melanoma and melanoma types, remains the most common neoplasm worldwide. Given its rising incidence, limitations of current therapies, and the challenges of effective prevention, novel therapeutic and preventive strategies are needed. One substance that has been the focus of growing attention is melatonin. This indolamine has garnered scientific interest due to its potential defensive effects against skin carcinogenesis. The aims of this article were to synthesize current evidence on the role of melatonin in the defense against skin cancer and propose its applicability as a preventive and adjuvant therapeutic agent to this type of cancer. A hypothesis-oriented narrative analysis was conducted using the MEDLINE/PubMed database, considering reviews and original articles published in English up to December 2025. Keywords related to melatonin, circadian rhythm, sleep disturbances, oxidative stress, and skin cancer biology were combined using Boolean operators. Experimental in vitro and in vivo studies, as well as available human data relevant to skin carcinogenesis were included. Beyond its participation in circadian rhythm regulation, melatonin exhibits antioxidant, anti-inflammatory, and immunomodulatory properties that directly influence skin cancer-related pathways. Evidence indicated that this indolamine protects against ultraviolet-induced DNA damage, modulates the tumor microenvironment, and regulates key molecular signaling cascades, like PI3K/Akt/mTOR and p53. Preclinical studies proposed that this hormone contributes to the control of oxidative imbalance, apoptosis, cell proliferation, and immune surveillance in both melanoma and non-melanoma skin cancer. We hypothesize that melatonin, owing to its diverse mechanisms of action, endogenous nature, and low toxicity at physiological levels or within targeted topical vehicles, may represent a promising complementary strategy for the prevention and adjuvant management of skin malignancies. Further clinical and experimental research is essential to validate the potential of this hormone as a novel agent in dermatologic oncology.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"318 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-026-04933-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}